### Clinical Oversight Review Board (CORB) Criteria for Prescribing

### Tildrakizumab-asmn (Ilumya)

#### Notes:

- Quantity Limits: N/A
- ^ Adequate trial is defined as the following:
  - Phototherapy 8 weeks
  - Systemic non-biologics for psoriasis 6 weeks
  - o Biologics 12 weeks
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **tildrakizumab-asmn (Ilumya)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

#### Initiation (new start) criteria:

- 1. Prescriber is a dermatologist and patient has a diagnosis of plaque psoriasis
  - Patient has failed an adequate trial^ of phototherapy (unless documented by prescriber phototherapy not appropriate)
  - Patient has failed an adequate trial<sup>^</sup>, or patient has an allergy or intolerance<sup>\*</sup> to, at least 1 of the following (or contraindication to all):
    - Methotrexate
    - Acitretin
    - Cyclosporine
  - Patient has failed an adequate trial, or patient has an allergy or intolerance to all of the following:
    - Adalimumab product (criteria based)
    - Secukinumab (criteria based)
    - Ustekinumab (criteria based)
    - Guselkumab (criteria based)
    - Risankizumab-rzaa (criteria based)

# <u>Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:</u>

- 1. Prescriber is a dermatologist and patient has a diagnosis of plague psoriasis
  - Patient has tried and failed, or patient has an allergy or intolerance\* to all of the following:
    - Adalimumab product (criteria based)
    - Secukinumab (criteria based)
    - Ustekinumab (criteria based)

kp.org

Revised: 06/13/24 Effective: 08/01/24 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



### Clinical Oversight Review Board (CORB) Criteria for Prescribing

# Tildrakizumab-asmn (Ilumya)

- Guselkumab (criteria based)
- Risankizumab-rzaa (criteria based)

kp.org

Revised: 06/13/24 Effective: 08/01/24



All plans offered and underwritten by

